{"id":"icosapent-ethyl-ipe","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Atrial fibrillation"},{"rate":null,"effect":"Musculoskeletal pain"},{"rate":null,"effect":"Gout"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IPE is an omega-3 fatty acid that acts as a substrate for lipid-lowering pathways, reducing hepatic triglyceride synthesis and increasing triglyceride clearance. It also has anti-inflammatory properties through modulation of eicosanoid production and may reduce cardiovascular risk through multiple mechanisms including effects on blood viscosity and endothelial function.","oneSentence":"Icosapent ethyl is a purified ethyl ester of eicosapentaenoic acid (EPA) that reduces triglyceride levels and modulates lipid metabolism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:29.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia in patients on statin therapy"},{"name":"Cardiovascular risk reduction in patients with elevated triglycerides"}]},"trialDetails":[{"nctId":"NCT06720662","phase":"NA","title":"Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk Cardiovascular Disease.","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-04-01","conditions":"Atherosclerosis Cardiovascular Disease","enrollment":294},{"nctId":"NCT02719327","phase":"PHASE2, PHASE3","title":"Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2017-06-08","conditions":"Alzheimer's Disease","enrollment":131},{"nctId":"NCT04562467","phase":"PHASE4","title":"The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk","status":"COMPLETED","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2020-09-24","conditions":"Cardiovascular Diseases, Cardiovascular Risk Factor, Triglycerides High","enrollment":70},{"nctId":"NCT04460651","phase":"PHASE3","title":"PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial","status":"COMPLETED","sponsor":"Estudios Clínicos Latino América","startDate":"2020-08-14","conditions":"COVID19","enrollment":4093}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":108,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vascepa®","Vascepa"],"phase":"phase_3","status":"active","brandName":"Icosapent ethyl (IPE)","genericName":"Icosapent ethyl (IPE)","companyName":"Estudios Clínicos Latino América","companyId":"estudios-cl-nicos-latino-am-rica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Icosapent ethyl is a purified ethyl ester of eicosapentaenoic acid (EPA) that reduces triglyceride levels and modulates lipid metabolism. Used for Hypertriglyceridemia in patients on statin therapy, Cardiovascular risk reduction in patients with elevated triglycerides.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}